<qa>  What is the outcome of the trial of cetuximabbevacizuma13. Saltz, L.B., et al. Randomized phase II trial of cetuximabbevacizumabirinotecan CBI versus cetuximabbevacizumab CB in irinotecan-refractory colorectal cancer. in Proc Am Soc Clin Oncol. 2005. 